Similarly to the in vitro findings, our in vivo results indicated that the combination of SH003 and DTX suppressed tumor growth and decreased p-EGFR (Y1068) and p-STAT3 (Y705) expression compared with the control in the NSCLC xenograft model. This evidence concerns the gene EGFR and non-small cell lung carcinoma.